Evommune, Inc.
EVMNDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How EVMN's past catalysts played out
EVO101
Atopic Dermatitis Eczema
Oral EVO756
Chronic Inducible Urticaria
EVO756
Chronic Spontaneous Urticaria
EVO301
Atopic Dermatitis (AD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EVO101 | Phase 2 | Atopic Dermatitis Eczema | - | - |
Oral EVO756 | Phase 2 | Chronic Inducible Urticaria | - | - |
EVO756 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
EVO301 | Phase 2 | Atopic Dermatitis (AD) | - | - |
Frequently asked questions
What is in Evommune, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Evommune, Inc.'s (EVMN) pipeline across Phase 2. Its lead program is EVO101 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Evommune, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Evommune, Inc. (EVMN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EVMN biotech catalysts?→
Add EVMN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Evommune, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.